|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910828494103321 |
|
|
Titolo |
Generic drug product development : specialty dosage forms / / edited by Leon Shargel, Isadore Kanfer |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
New York, : Informa Healthcare USA, c2010 |
|
|
|
|
|
|
|
ISBN |
|
0-429-13292-1 |
1-282-56098-0 |
9786612560989 |
1-4200-2003-X |
|
|
|
|
|
|
|
|
Edizione |
[1st ed.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (292 p.) |
|
|
|
|
|
|
Collana |
|
Drugs and the pharmaceutical sciences ; ; 204 |
|
|
|
|
|
|
Altri autori (Persone) |
|
ShargelLeon <1941-> |
KanferIsadore |
|
|
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Generic drugs |
Drug development |
Drugs - Dosage forms |
Drugs - Therapeutic equivalency |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Front Cover; Preface; Contents; Chapter 1. Introduction; Chapter 2. Nonsystemically Absorbed Oral Drug Products; Chapter 3. Topical Drug Products - Development, Manufacture, and Regulatory Issues; Chapter 4. Assessment of Topical Dosage Forms Intended for Local or Regional Activity; Chapter 5. Rectal Dosage Forms and Suppositories; Chapter 6. Nasal and INhalation Drug Products; Chapter 7. Locally Acting Nasal and inhalation Drug Products: Regulatory and Bioequivalence Perspective; Chapter 8. Transdermal Dosage Forms |
Chapter 9. Pharmaceutical Development of Modified-Release Parenteral Dosage Forms Using Bioequivalence (BE), Quality by Design (QBD), and In Vitro In Vitro Correlation (IVIVC) Principles Chapter 10. Biosimilar Drug Products - Manufacture and Quality ; Index; Color Insert ; Back Cover |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
Generic Drug Product Development: Specialty Dosage Forms explores the issues related to providing evidence of pharmaceutical equivalence and bioequivalence for specialty drug products. It describes various |
|
|
|
|